"I believe that Genentech occupies a unique intersection of scientific excellence and data-driven cross-functional drug development."
I joined the Safety Assessment group at Genentech in 2010 and initially focused on developing small molecule and antibody drug conjugate therapies for oncology. I then transitioned to supporting our ophthalmology franchise, and I now serve as the Toxicology Therapeutic Area Leader for ophthalmology. In this capacity, my group focuses on assessing the safety of novel treatments for retinal diseases and works to develop these molecules from target identification through post-marketing. In addition, I am privileged to lead the gRED Ophthalmology Platform Team. This team serves as translational development team for novel ocular delivery technologies and supports the gRED/Roche ophthalmology portfolio as a whole.
Prior to joining Genentech, I served as a discovery and regulatory toxicologist at the Schering-Plough Research Institute, developing early and late stage products across numerous therapeutic areas, and acting as an expert on formulation safety assessment. I received my B.S. in Biochemistry from the University of Vermont, and a Ph.D. in Molecular and Environmental Toxicology from the University of Wisconsin-Madison, where my research focused on the role of the Aryl Hydrocarbon Receptor (AhR) in cardiovascular development. After graduation, I pursued postdoctoral studies focused on cardiovascular developmental toxicology at the University of New Mexico and the Lovelace Respiratory Research Institute.
Regul Toxicol Pharmacol. 2017 Jun;86:221-230.
My main focus is on the development of novel therapies for retinal diseases and ocular drug delivery systems to reduce dosing frequency. The intravitreal administration of drugs is a relatively new field, so in additional to applied nonclinical toxicology studies, my group also engages in investigational toxicology and basic ocular biology research. In addition, I support the Genentech portfolio as a whole as a subject matter expert on formulation, counter ion, and drug delivery systems toxicology.